
Lundbeck
Lundbeck is a global pharmaceutical company specialized in brain diseases.
HQ location
Copenhagen, Denmark
Website
Launch date
Employees
Market cap
$4.2b
Enterprise value
$5.5b
Share price
DKK30.55 LUN.CO
Recent deals
Corporate Venture Fund
loading funding rounds…
DKK | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
---|---|---|---|---|---|---|---|
Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
% growth | (8 %) | 12 % | 9 % | 11 % | 9 % | 6 % | - |
EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
% EBITDA margin | 23 % | 26 % | 28 % | 29 % | 29 % | 29 % | 29 % |
Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
% profit margin | 8 % | 11 % | 12 % | 14 % | 15 % | 16 % | 17 % |
EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article, Equity research estimates
Related Content
Analytics
Unlock the full power of analytics with a premium account
Track company size and historic growth
Track team composition and strength
Track website visits and app downloads
Tech stack
Tech stackLearn more about the technologies and tools that this company uses.
Investments analysisEdit
By Industry
By Round
Investments by Lundbeck
Edit
ACQUISITION by Lundbeck May 2019

ACQUISITION by Allergan Jul 2015

ACQUISITION by Lundbeck Mar 2009

ACQUISITION by Lundbeck Sep 2019

ACQUISITION by Lundbeck May 2014

exited

ACQUISITION by Lundbeck Mar 2018

ACQUISITION by Lundbeck Oct 2024